secwatch.observer — SEC 8-K summary
======================================

Issuer:     INSMED Inc (INSM)
CIK:        0001104506
Form:       8-K
Filed at:   2025-02-20T23:59:59+00:00
Accession:  0001140361-25-005190
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Insmed reports Q4 ARIKAYCE revenue $104.4M; brensocatib NDA accepted with Priority Review
--------------------------------------------------------------------------------

- Full-year 2024 ARIKAYCE revenue $363.7M (+19% YoY); Q4 net loss $235.5M ($1.32/share).
- Brensocatib NDA for bronchiectasis accepted by FDA with Priority Review; PDUFA date Aug 12, 2025.
- Company reiterates FY2025 ARIKAYCE revenue guidance $405M–$425M (11-17% YoY growth).
- Cash, equivalents, and marketable securities approx. $1.4B as of Dec 31, 2024.
- Director Alfred Altomari will not stand for re-election at 2025 Annual Meeting; no disagreement.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1104506/000114036125005190/0001140361-25-005190-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1104506/000114036125005190/ef20043928_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-25-005190

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer